Lokavant provides a clinical trial intelligence platform for pharmaceutical sponsors and CROs. The company offers tools for enrollment timeline analysis, scenario planning, and site/country selection optimization in clinical trials.

Lokavant

SAIMOS is specialized in geoinformation systems, video analytics, AI, and custom developments in the areas of security and infrastructure.

SAIMOS

Lokavant is a clinical intelligence company that improves trial execution through its data-driven analytics platform. 
Lokavant’s platform helps study teams aggregate and integrate data in real-time from disparate trial data sources, and is powered by advanced analytics  to proactively manage and monitor studies, surfaces insights and drive efficiencies through risk-based monitoring, operational study health tracking, trial planning and benchmarking, medical monitoring, and more.

Roivant Sciences

Edison Partners

Mitsui & Co

Last week, we shared the impacts of different therapeutic areas and sponsors with their impact on participant discontinuation risk in #clinicaltrials 

⚡️In isolation, COVID-19 was not an important factor in increasing participant discontinuation risks.

⚡️What proved more meaningful were the effects of the sponsors and therapeutic areas themselves – the more complex the protocol, and the more exploratory endpoints, the higher the risk of participant discontinuation.

But can we expect different discontinuation risk for trials in different geographies?

It shouldn’t be too surprising that there are varying participant discontinuation risks across regions across the world, as we see here.

Link to the whitepaper in the comments 👇

#covid #clinicalresearch 

Rohit Nambisan, Todd Johnson, Andrew (AJ) Mills, Meredith Dees

🌟 Shout out to our Gold Sponsor, Lokavant

Why we are excited to partner with Lokavant
The Innovation Network has identified 1) trial timelines and 2) real applications of AI as key areas of needed thought leadership. Lokavant works and leads at the intersection of both.

Lokavant was born within Biopharma to improve clinical trial performance by providing study teams with a Clinical Trial Intelligence Platform that delivers real-time, AI-driven data insights to enable researchers to design, plan, and execute trials more efficiently while boosting their confidence in making well-informed decisions.

Thank you, Lokavant, for your unwavering dedication to step forward.
🔗 Learn more about them: www.lokavant.com

💌 Nominate a decisionmaker, change agent, or emerging leader. (Or, if you might be so bold, nominate yourself!)
https://lnkd.in/gCy4RWhT 

#Lokavant #InnovationNetwork #ClinicalTrial

Enhancing diversity to ensure efficacy in clinical trials

Clinical Trials are becoming more effective every day, but there´s still work to be done to ensure the development of safe and efficacious medicines for those who need them most.

How can we keep moving forward and increase participant representation in #clinicaltrials.

Identifying patients for clinical research is particularly challenging, especially when targeting diseases affecting diverse participant cohorts.

In his latest Forbes Technology Council article, Lokavant's CEO Rohit Nambisan shares his thoughts about the first step to greater representation, and how researchers can avoid misrepresentations in clinical trials. 📄 

👉 Read the full article here.https://https://lnkd.in/dbK7p2QG 

#Clinicalresearch #AI

Running Strategic Feasibility in #ClinicalResearch for an upcoming trial is often a slow and inaccurate process...

Highlighted by the simple facts that:

1.   Sponsors are only 58% confident in feasibility assessments.
2.   91% of feasibility assessments "have short turn-around times" and
3.   78% of feasibility assessment have poor data collection mechanisms to power their forecasts.

Sound familiar?

With the Launch of Spectrum, Lokavant's #AI optimized Feasibility solution, these challenges may be a thing of the past.

Case-in-point
Recently, a top-10 Pharmaceutical Sponsor leveraged Spectrum to achieve their goal of identifying the most suitable sites for a critical phase III Obstructive Hypertrophic Cardiomyopathy(oHCM) #clinicaltrial; ensuring their plan remained on target 🎯 .

🔍 Discover how Spectrum is transforming clinical trials by reading our case study below and here: https://lnkd.in/dwM3E7tY

cc Rohit Nambisan Aaron Mackey

Thank you TrialSite News for your support of Spectrum, the first AI-Optimized Trial Feasibility solution. We are proud to see our technology enhancing clinical research. 🙌 

Together, let´s continue changing lives through health innovation. 🤖 💊  
 
 👉 Read the article here. 
https://lnkd.in/dKhAPqwf

#HealthInnovation #ClinicalTrials #AI #TrailSiteNews

Last week, our team at Lokavant came together for an unforgettable offsite in Denver! 🌲 

From team-building adventures to vision and strategy sessions --- we made the most of every moment.

We focused most of our time on product development strategies to support our vision to make #ClinicalTrial Intelligence truly transformational. 

Highlights included:
- Hikes in the Rockies 🏞️
- Billiards (Pool), with competition from teams of Product vs. Commercial 🎱 
- Planning sessions about the world of #AI in #ClinicalResearch🤖

Here’s to many more successful retreats and milestones together! 🚀

cc Rohit Nambisan  Doug Weatherhead Daniel Silva Aaron Mackey

Metric
Company Name	Lokavant	SAIMOS
Symbol
MSH ID	COM:LOKAVANT	DE:SAIMOS
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Technology
Industry	Clinical Research Technology	Security and Surveillance
Country	US	DE
Stage
Employee Count	29
Website	lokavant.com	saimos.de
LinkedIn	lokavant	saimos-ong-it-gmbh
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

LOKA

COM:LOKAVANT

Lokavant

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue